$8.38
4.45% today
Nasdaq, Apr 04, 09:17 pm CET
ISIN
KYG8807B1068
Symbol
TBPH
Sector
Industry

Theravance Biopharma Inc Stock price

$8.77
-0.38 4.15% 1M
+0.67 8.27% 6M
-0.64 6.80% YTD
-0.52 5.60% 1Y
-0.73 7.68% 3Y
-14.07 61.60% 5Y
-8.50 49.22% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.24 2.66%
ISIN
KYG8807B1068
Symbol
TBPH
Sector
Industry

Key metrics

Market capitalization $433.86m
Enterprise Value $395.33m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.14
P/S ratio (TTM) P/S ratio 6.74
P/B ratio (TTM) P/B ratio 2.47
Revenue growth (TTM) Revenue growth 12.12%
Revenue (TTM) Revenue $64.38m
EBIT (operating result TTM) EBIT $-42.44m
Free Cash Flow (TTM) Free Cash Flow $-11.87m
Cash position $88.35m
EPS (TTM) EPS $-1.15
P/E forward negative
P/S forward 4.20
EV/Sales forward 3.83
Short interest 14.30%
Show more

Is Theravance Biopharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Theravance Biopharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Theravance Biopharma Inc forecast:

2x Buy
50%
2x Hold
50%

Analyst Opinions

4 Analysts have issued a Theravance Biopharma Inc forecast:

Buy
50%
Hold
50%

Financial data from Theravance Biopharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
64 64
12% 12%
100%
- Direct Costs 6.01 6.01
1% 1%
9%
58 58
14% 14%
91%
- Selling and Administrative Expenses 59 59
2% 2%
91%
- Research and Development Expense 36 36
7% 7%
56%
-36 -36
23% 23%
-57%
- Depreciation and Amortization 6.01 6.01
1% 1%
9%
EBIT (Operating Income) EBIT -42 -42
20% 20%
-66%
Net Profit -56 -56
2% 2%
-88%

In millions USD.

Don't miss a Thing! We will send you all news about Theravance Biopharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Theravance Biopharma Inc Stock News

Neutral
PRNewsWire
4 days ago
DUBLIN , March 31, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference in Las Vegas on Wednesday, April 9 at 11:30 am PDT (2:30 pm EDT/6:30 PM GMT). Members of Theravance Biopharma senior management will also be hosting one-on-one meetings at the conference.
Neutral
PRNewsWire
8 days ago
DUBLIN , March 27, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) supporting its selective and differentiated pharmacodynamic profile will be presented at the 77th Annual Meeting of the American Academy of Neurology (AAN) Meeting, taking pl...
Neutral
Seeking Alpha
about one month ago
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q4 2024 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants Rick Winningham – Chief Executive Officer Rhonda Farnum – Chief Business Officer Aziz Sawaf – Chief Financial officer Aine Miller – Head-Development Conference Call Participants Douglas Tsao – H.C. Wainwright Julian Harrison – BTIG David Risinger – Leerink Partners Operat...
More Theravance Biopharma Inc News

Company Profile

Theravance Biopharma, Inc. operates as a biopharmaceutical company. It focuses on the discovery, research, development, and commercialization of organ-selective medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Head office Cayman Islands
CEO Rick Winningham
Employees 97
Founded 2013
Website www.theravance.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today